Highest-materiality recent filing
Net sales $29.8M ($24.2M Tru Niagen); gross margin 64.8%; net income $1.0M ($0.01 EPS); adjusted EBITDA $3.0M.
Niagen Bioscience announces 2026 annual meeting voting results; all directors elected
All 8 director nominees elected: Rubin (28.5M for, 16.8M withheld) and Shahbazi (30.5M for, 14.7M withheld) had significant withhold votes.
Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M
Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.
Niagen Bioscience increases share repurchase authorization to $20M from $10M
Board approved increase of share repurchase program from $10M to $20M.
Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M
Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).
Niagen Bioscience sells ChromaDex Reference Standards business to LGC in all-cash deal
All-cash sale closed Feb 24, 2026; buyer is VHG Labs, part of LGC Group.
Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038
One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.
Niagen Bioscience authorizes $10M share repurchase program through October 2027
Board authorized up to $10M in common stock repurchases over ~2 years; expires Oct 31, 2027.
Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).
Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY
Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.
Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth
Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.
Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029
Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.
Stockholders approve 4.75M share increase to equity plan and new ESPP at annual meeting
Amendment to 2017 Equity Incentive Plan adds 4,750,000 shares; approved by 53,046,229 votes for.
Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook
Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).
ChromaDex rebrands as Niagen Bioscience; Nasdaq ticker becomes NAGE
Name change from ChromaDex Corporation to Niagen Bioscience, Inc. effective March 19, 2025.
ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M
Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).
Base salary increased to $650,000 effective Jan 1, 2025; target bonus raised to 75% of base for FY2025.
ChromaDex appoints Crowe LLP as new independent auditor effective December 13, 2024
Audit Committee approved Crowe LLP as independent auditor for fiscal year ending Dec 31, 2024, effective Dec 13, 2024.
Dartmouth waives ~$3.5M in accrued unpaid royalties, license fees, and maintenance expenses under exclusive license agreements.
ChromaDex amends ATM sales agreement; adds Roth Capital, removes B. Riley
Amendment dated Nov 20, 2024 to existing At Market Issuance Sales Agreement of June 12, 2020.
ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M
Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).
ChromaDex auditor Marcum resigns effective Oct 31 due to conflict from CBIZ merger
Marcum LLP resigned as independent auditor effective Oct 31, 2024, citing independence concerns from its impending merger with CBIZ Inc.
Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.
ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M
Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).
ChromaDex appoints James Lee as Interim CFO after Brianna Gerber resignation
Brianna Gerber resigned as CFO and Principal Accounting Officer effective July 12, 2024.
ChromaDex CFO Brianna Gerber resigns effective July 12; consulting transition through Aug 12
CFO & CAO Brianna Gerber resigns effective July 12, 2024; company beginning search for replacement.
All eight director nominees elected: Jaksch, Fried, Rubin, Yu, Ng, Patrick, Cohen, Shahbazi.
ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth
Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).
ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M
Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).
Revolving credit line of up to $10M extended to November 12, 2025; no amounts outstanding as of filing.
ChromaDex reports Q3 2023 net sales $19.5M (+14% YoY), positive adjusted EBITDA $0.5M
Total net sales $19.5M (+14% YoY); Tru Niagen sales $17.4M (+19% YoY).
ChromaDex Q2 2023: Net sales $20.3M (+21%), positive Adj EBITDA, raises FY23 guidance to ≥15% growth
Net sales $20.3M, up 21% YoY; Tru Niagen sales $16.9M (+16%).
ChromaDex shareholders approve equity plan increase, reject preferred stock authorization
Stockholders approved amendment to 2017 Equity Incentive Plan, increasing shares available by 3.65M.
ChromaDex Q1 revenue $22.6M (+31% YoY), net loss narrows to $1.9M, raises 2023 outlook
Record Q1 net sales $22.6M (+31% YoY); Tru Niagen contributed $17.6M.
ChromaDex amends bylaws to align with universal proxy rules and DGCL changes
Board amended and restated bylaws on March 16, 2023, effective immediately.
ChromaDex Q4 revenue $21.0M (+18% YoY), Adj EBITDA turns positive at $0.4M
Q4 net sales $21.0M (+18% YoY); Tru Niagen sales $16.1M (+14% YoY).
ChromaDex names Brianna Gerber CFO effective Jan 1, 2023; salary $325K
Brianna Gerber appointed CFO after serving as interim CFO since August 2022.
ChromaDex Q3 net sales $17.1M, net loss narrows to $1.0M; approaches cash flow breakeven
Net loss of $1.0M ($0.01 loss per share) vs $8.8M loss in Q3 2021; Adjusted EBITDA loss narrowed to $1.2M.
ChromaDex expands Nestlé Health Science supply deal to supplements; Nestlé invests $5M
New 5-year supply agreement gives Nestlé non-exclusive rights to sell Niagen in dietary supplements, medical nutrition, and functional foods.
ChromaDex forms China JV for Tru Niagen, sells $3.1M stock to insiders at $1.25/sh
Taikuk invests $1M for 11% non-voting stake in JV to commercialize Tru Niagen in China; Blue Hat registration required within 24 months.
ChromaDex Q2 net sales $16.7M (-5% YoY); CFO Farr terminated, Gerber interim CFO
Net sales $16.7M, down 5% YoY; Tru Niagen sales $14.5M (-6%). Gross margin 60%. Net loss $6.4M ($0.09 loss per share).
All seven director nominees elected at June 16 annual meeting; votes ranged from ~28.3M to ~37.3M for.
ChromaDex founder Frank Jaksch resigns as executive director and employee; remains chairman
Frank L. Jaksch, Jr. resigns as executive director and employee effective June 30, 2022.
ChromaDex forms JV to commercialize Tru Niagen in China; gets 71% voting interest
JV partners Crystal Lake, Pioneer Idea, Taikuk contribute $1.8M, $1.2M, $1.0M total $4M into the JV.
ChromaDex Q1 net sales $17.3M (+18% YoY); net loss $7.7M; adj EBITDA loss narrows
Net sales $17.3M (+18% YoY); Tru Niagen sales $14.9M (+20% from Q1 2021).
ChromaDex announces director retirement and appointment of two new independent directors
Stephen Block to retire from board at 2022 annual meeting; not due to any disagreement.
Chromadex director Caroline Levy resigns from board and committees
Levy resigned effective April 11, 2022; no disagreement with the company cited.
Director Kurt Gustafson not seeking re-election at June 2022 annual meeting
Gustafson notified ChromaDex on April 5, 2022 of decision.
ChromaDex board member Jeffery Baxter resigns effective April 4, 2022
Jeffery Baxter resigned from the board and its Audit and Nominating/Governance committees on April 4, 2022.
ChromaDex provides 2022 outlook: net sales +15-20% YoY; Tru Niagen revenue $56.7M in 2021
2021 net sales $67.4M (+14% YoY); Tru Niagen sales $56.7M; gross margin 61.5%.
On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024
Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.
On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.
As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.
On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).
appointed Brianna Gerber as Chief Financial Officer of the Company, effective as of January 1, 2023.
On August 8, 2022, the Board appointed Hamed Shahbazi as a member of the Board effective as of August 9, 2022, to serve until the Company’s 2023 annual meeting of stockholders and until his successor is duly elected and qualified.
On August 10, 2022, the Board of Directors of ChromaDex (the “Board”) appointed Brianna Gerber as SVP, Finance / Interim Chief Financial Officer, effective as of August 11, 2022, to replace the vacancy created by Mr. Farr’s termination as disclosed in item (a) above.
On August 10, 2022, Kevin Farr was terminated without cause as Chief Financial Officer of the Company, and as an officer, employee, and director of the Company and any subsidiaries of the Company in which he serves in any of those capacities, effective as of August 12, 2022.
On June 3, 2022, Frank L. Jaksch, Jr. notified ChromaDex Corporation (the “Company”) of his intention to resign as executive director and employee of the Company
On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.
On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.
Max materiality 0.85 · Median 0.65 · Most common event earnings